---
name: research-log-2026-10-09
description: Planning feasibility review and Virtual Biotech-centered peer survey
metadata:
  type: project
date: 2026-10-09
---

# Research log — October 9, 2026

Objective: review both planning documents for framework feasibility, validation/benchmark data access, risk and peers. User steering: prioritize Virtual Biotech and related systems already covered by the critical review.

Method: seed-driven primary-source review, backward references from R2E to genetic-support/locus-to-gene work, statistical-genetics methodology checks, and focused additions on process/preclinical benchmarks. Academic-research MCP was not exposed, so web retrieval and public repository requests were used. This was not a systematic review.

Created [[TETHER Feasibility Analysis and Peer Survey]] and supporting access audit, reproducible power approximation, and peer-survey inventory in `planning/review-assets/`. The original planning notes were preserved.

Key additions relative to the existing notes: distinction between model reliable knowledge and training cutoff; announced comparison-model retirement; actual endpoint/progression label missingness; controlled-access UKB-PPP caveat; agent network bypass; supervised-scorer attribution controls; cluster/censoring-aware benchmark design; updated process and preclinical benchmark positioning.

No agent execution, model billing, account creation, full biomedical-dataset restoration, MR analysis, empirical power simulation or prospective predictions occurred. HTTP failures and incomplete source inspections are recorded explicitly.

Recommended next step: benchmark-first feasibility phase with model/source/label/power/attribution gates, as described in [[project-goals]]. Staffing and budget remain assumptions. See [[tether-feasibility-findings]] for dated facts and source references.

## Follow-up: revalidated data scaffold implemented

The user selected a plan-and-scaffold first setup, requested revalidation, then explicitly authorized implementation. Created [[data/README|data workspace documentation]], [[data/DATA_PLAN|the full data requirements/compatibility/roadmap]], the provider/product JSON catalog, empty storage/evaluation folders, data ignore rules and a sanitized public metadata observation manifest. Updated [[project-goals]] and [[data-acquisition-plan]].

The catalog has 83 providers and 177 planned products. It includes all source families and the Virtual Biotech 38-component inventory, with separate access/temporal/collection statuses, task/ablation linkage, unconditional/conditional dependencies, overlap, costs and unresolved fields.

Fresh metadata checks confirmed archive layouts and legacy Genetics directories. eQTL Catalogue's current release notes strengthened the need to pin content/metadata rather than stable dataset IDs alone. The original planning documents were preserved; dataset accounts, payload collection, analysis, model runs and ingestion code were not part of this implementation.

Scaffold verification passed: catalog JSON/IDs/references, source and 177-row index coverage, no unconditional dependency cycles, new wiki links, restricted-profile defaults and uncollected/unparsed/unvalidated states. Nineteen ignore-rule cases passed in an isolated temporary Git repository. Original planning/feasibility file hashes were unchanged.
